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APPLICATION OF THE NON-LINEAR BLINDER-OAXACA DECOMPOSITION TO
STUDY RACIAL/ETHNIC DISPARITIES IN ANTI-OBESITY MEDICATION USE
Mehta HB, Rajan SS, Aparasu RR, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: The Blinder-Oaxaca (BO) decomposition helps to identify the causes
of disparity between two groups based on observed characteristics, and quantifies
the residual disparity due to unobserved heterogeneity. This study uses the non-
linear BO decomposition, an extension of the original BO decomposition, to iden-
tify and quantify the observed causes behind the racial/ethnic disparity in anti-
obesity medication use among US adults who met the medical criteria to receive
these medications. METHODS: The Medical Expenditure Panel Survey data, 2002-
2007, was used in this retrospective cross-sectional study. Themedical criteria was
defined as adults (age20 years) with bodymass index (BMI)30, or with BMI27
and comorbidities such as hypertension, cardiovascular diseases, diabetes or hy-
perlipidemia. The non-linear BO decomposition method was used to identify the
contribution of each observed socio-demographic and health characteristic in ex-
plaining the racial/ethnic disparity and to estimate the residual unexplained
disparity. RESULTS: A total of 395,319,750 adults met medical criteria from 2002-
2007; of which, 0.61% used anti-obesity medications. The proportion of medically
eligible Blacks using anti-obesitymedicationwas 33% lower thanWhites. The non-
linear BO decomposition method revealed that only marital status explained the
racial/ethnic disparity among the observed characteristics. Blacks were younger,
had a higher proportion of women in the sample, and had a higher BMI, and these
characteristics were the chief determinants of increased anti-obesity medication
use. Thus, the decomposition estimated that if the blacks had similar characteris-
tics as the whites the observed disparity in the sample would have been 58%
higher. CONCLUSIONS: The decomposition revealed interesting but disconcerting
findings. None of the differences in the observed socio-demographic and health
characteristics (except marital status) successfully explained the racial disparity.
Thus, further exploratory studies examining racial differences in individual beliefs,
behavioral patterns and provider prescription patterns are vital to understand
these disparities.
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OBJECTIVES: The US ranks first among all developed countries for obesity/over-
weight prevalence. Anti-obesity medications may help address this public health
problem, but national utilization data for anti-obesity medications is lacking. The
study objective was to examine trends in anti-obesity medication use among
adults who met medical criteria (MC) and understand the extent of use of such
medications among adultswho did notmeetMC.METHODS:A retrospective cross-
sectional study was performed using the Medical Expenditure Panel Survey data
from 2002-2007. The study comprised all non-pregnant adults (20 years of age;
N210,829,728). Meeting the MC for anti-obesity medication use for an individual
was defined as having Body Mass Index (BMI)  30 (clinically obese) or having BMI
 27 with comorbidities such as hypertension, cardiovascular disease, diabetes
and hyperlipidemia. Anti-obesity medications were identified from prescription
medicine files using national drug codes and drug names. Proportions of anti-
obesity medication users among adults whomet MC were calculated for each year
and logistic regression was performed to test utilization trends. Descriptive anal-
ysis was conducted to assess proportion of adults using anti-obesity medications
who did not meet MC. RESULTS: Of the adults who met MC (N65,886,625), 0.52%
were taking anti-obesity medications. Analysis of multiyear data showed no sta-
tistically significant trend (p-value  0.25) in anti-obesity medication use among
adultswhometMC from2002 to 2007. Of all US adultswhowere taking anti-obesity
medications (N542,297), 31.98% did not meet MC for use. CONCLUSIONS: Less
than one percent of eligible adults used anti-obesity drugs in each year and anti-
obesity medication use did not change from 2002 to 2007. Almost one third of
anti-obesity medication users did not meet MC. Given the associated side-effects
for these medications, further research is needed to understand the use of anti-
obesity medications among adults who do not meet MC.
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CONTROLLED SUBSTANCE PRESCRIBING AND UTILIZATION OF PRESCRIPTION
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OBJECTIVES:Over 40 states have prescription drugmonitoring programs (PDMP) to
monitor the utilization of controlled substances (CS) with the goal of reducing drug
abuse and diversion. Little is known about how PDMPs are actually used by health
care professionals. The purpose of this paper is to review how prescribers utilize
PDMPs and to assess the impact of a PDMP onCS prescribing.METHODS:The paper
uses data from the Kentucky All Schedule Prescription Electronic Reporting Pro-
gram (KASPER) from 2002-2009. We review CS prescribing and KASPER utilization
using descriptive statistics, visualization, and t-test, controlling for characteristics
of KASPER users, the number of KASPER requests for each user type, and geo-
graphic distribution. Statistical analysis is conducted in STATA v11.0. RESULTS: CS
prescriptions issued by Kentucky prescribers increased from 8.4 million in 2002 to
over 11million in 2009. During this period, KASPER system requests increased from
100,000 in 2002 to more than 530,000 in 2009. Yet, most CS prescribers (64%) do not
have KASPER accounts. Comparing KASPER users across geographic regions, rural
areas have a higher (49%) rate of KASPER use than urban areas (32%, p.05). For CS
prescribing, the typical KASPER account holder issued 1,665 prescriptions a year in
2009, compared to 250 prescriptions issued by non-account holders. The top CS
prescriber in 2009 issued over 41,000 prescriptions, an increase of 60% from the top
prescriber in 2005. Finally, CS prescribing has become skewed, with 10% of pre-
scribers issuing 95% of all CS prescriptions. CONCLUSIONS: Since 2004, CS pre-
scribing in Kentucky has increased by 40% and KASPER system requests have in-
creased by 400%. The most interesting finding is that the majority of growth in CS
prescribing is froma relatively small number of prescribers.Whether this finding is
a direct result of the PDMP is a question for further research.
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OBJECTIVES: Studies have shown that despite the national guidelines recommend-
ing counseling for obese patients, counseling rates during outpatient visits remain
low. We determined the trends for obesity counseling (diet, exercise and weight
reduction) from year 2005 to 2008 and the association between being clinically
diagnosed with obesity and being counseled, for obese adults during their outpa-
tient visits. We also determined if clinical diagnosis of obesity varied with obesity
class which is classified by BMI. METHODS: We used the data from 2005 to 2008
National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambu-
latory Medical Care Survey (NHAMCS). The study included all adults having Body
Mass Index (BMI)  30. The outcome of interest was whether the patient received
obesity counseling or not. RESULTS: 478 million patients had BMI  30 of which
only 6%were clinically diagnosedwith obesity, and 31% received counseling. There
was no statistically significant change in counseling for obese adults from the year
2005 to 2008. Patients clinically diagnosed with obesity had 7.7 times (95% CI: 5.3-
11.1) greater odds of receiving counseling as compared to undiagnosed obese pa-
tients after controlling for sociodemographic and clinical factors. Moreover, class II
(35.5 BMI39.9) and class III (BMI40) obese patients had 1.8 (95%CI: 1.4-2.4) and
4.5 (95%CI: 3.4-6.0) times greater odds of being diagnosedwith obesity as compared
to class I (30 BMI  34.4) obese patients. CONCLUSIONS: Being clinically diag-
nosed with obesity is an indicator of access to care, and the patient’s initiatives to
seek obesity-related care. Our finding of low rates of counseling for diet, exercise or
weight reduction during visits by obese patients indicates that obesity is commonly
under-diagnosed. Interventions should focus on patient awareness strategies to
increase the rate of clinical diagnosis and hence counseling.
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OBJECTIVES: Obesity is a major cause of morbidity and mortality and a rising
epidemic worldwide. Despite guideline recommendations, many obese patients
fail to receive adequate medical care. The objectives of the study were to examine
predictors of obesity treatment and assess differences in receiving treatment be-
tween various age groups. METHODS: The study used data from 2006-2008 Na-
tional Ambulatory Medical Care Survey and National Hospital Ambulatory Medical
Care Survey. Adults with age  20 years were included and obesity was defined as
having a BMI 30. Obesity treatment was defined as the receipt ofmedication (like
Sibutramine, Orlistat, etc.) and/or obesity counseling in terms of weight reduction,
exercise, or diet counseling. Splines were constructed to assess changes in obesity
treatment with age. Descriptive statistics andmultivariate logistic regression were
used to determine predictors of receiving obesity treatment. RESULTS: Out of 3.1
billion visits, 29.2% (95%CI:28.1–30.3%) were obese. Among those, 31.4% (95%CI:
28.2–34.6%) between ages 20-39; 32.5% (95%CI:29.6–35.4%) between ages 40-64 and
25.4% (95%CI:22.2–28.7%) above 64 years received treatment. Inmultivariatemodel,
a unit increase in age increased the likelihood to receive treatment by 1.8% (95%CI:
0.1–3.6%)within the age group 20-39 years; decreased the likelihood by 1.4% (95%CI:
2.3–0.4%)within 40-64 years; and decreased the likelihood by 3.4% (95%CI:5.0–1.7%)
above 64 years. Primary care physicians (OR–1.66, 95%CI:1.38-1.99), were approxi-
mately 70% more likely to provide treatment compared to specialists. Individuals
with comorbidities were more likely to receive treatment (OR-1.37, 95% CI:1.17-
1.60). A significant difference across geographical region was also observed.
CONCLUSIONS: Study suggests differences in obesity management across age
groups. Older adults were less likely to receive obesity treatment. Further research
is needed to ensure that quality care is provided across all age groups.
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OBJECTIVES: To examine prevalence of chronic comorbid diseases among obese
adults in the United States METHODS: Medical Expenditure Panel Survey Data
from2005 – 2007was used for the analysis. Adultswith age 20 years and BMI 30,
were defined obese. Unadjusted age-specific prevalence of hypertension, diabetes,
dyslipidemia, CHD, osteoarthritis and asthma were obtained among obese, non-
obese and entire population using descriptive analysis. Adjusted prevalence esti-
mates were obtained using regression analysis after controlling for socio-demo-
graphic factors. Age-specific prevalence ratios (relative risk) were obtained by
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